NVSEF News and Press, Novartis Ag Basel Akt From 10/25/22

Summary Novartis reported revenues and earnings that were down year over year. Currency rate movements were responsible for that, however, Novartis' underlying performance was pretty solid. The company offers a nice dividend yield and should be able to deliver very solid retur...

Summary BioLife recently formed a strategic partnership with CSafe to expand its service repertoire for its customers. The latest quarter reported extremely strong growth across all operations. While the company seemingly fixed most issues, the former COO (Rod de Greef) recent...

Summary Novartis will IPO its generic division. We estimate a lower Sandoz valuation (still at a premium compared to its peers) and higher losses of exclusivity. We derive a target price of CHF 80 with a 13x P/E on 2023 numbers. Here at the Lab, we used to be more ...

Summary Dividends are an important source of income for investors of all types but especially those that rely on their investments in retirement. The ideal characteristics of a dividend payer depend on whether the dividend will be reinvested or not. My ideal dividend payer acc...

Summary DTH invests in high yield stocks of developed countries, excluding North America. 52% of assets is in 3 countries: Japan, the U.K. and Australia. 54% is in 3 sectors: financials, materials and communication. Valuation looks attractive, but inflation-adjusted total ...

Summary Novartis AG broke into a downtrend and seems headed towards its next support, which could be seen as the next important catalyst. Novartis stock is seemingly a laggard, underperforming its industry reference and the broader healthcare sector, but is recently showing more r...

Summary If you adhere to the rules of the Cash Management Discipline, you build positions in very small increments. That and judicious use of hedging will help you surf the ups and downs of this volatile stock market. I have been trading in and out of my oil favorites in my tr...

Summary As a small logistics operator servicing other celllular therapy innovators, Cryoport is powered by the prudent merger/acquisition growth approach. Regardless of the bear market, Cryoport has been enjoying huge topline growth from successful acquisitions. Asides from bu...

Summary In collaboration with stellar partners like Vertex, Crispr is aggressively expanding its robust pipeline of gene-edited medicine for various disorders. By year end, Crispr is poised to file a marketing application in Europe for exa-cel, a drug designed to treat blood disor...

Summary Teva Pharmaceutical's divestments have been many in recent years, and the company presents a different set-up than in the past. In about 5 years Teva Pharmaceutical has reduced its net debt by $14 billion, a remarkable sum for a company with a market cap of only $10 billio...